CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Genotype-Guided Strategy for Oral P2Y12 Inhibitors Radionuclide Image-Guided Repair of the Heart State of the Art in Noninvasive Imaging of Ischemic Heart Disease and Coronary Microvascular Dysfunction in Women: Indications, Performance, and Limitations Percutaneous Coronary Intervention for Chronic Total Occlusion—The Michigan Experience: Insights From the BMC2 Registry Patient Characteristics Associated With Antianginal Medication Escalation and De-Escalation Following Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the OPEN CTO Registry 2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques PCI and CABG for Treating Stable Coronary Artery Disease Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives

Review ArticleVolume 75, Issue 11, March 2020

JOURNAL:J Am Coll Cardiol. Article Link

Select Drug-Drug Interactions With Direct Oral Anticoagulants

BS Wiggins, DL Dixon, RR Neyens et al. Keywords: DOACs; drug-drug interactions; P-glycoprotein

ABSTRACT


Millions of individuals in the United States require long-term treatment with an oral anticoagulant. For decades, vitamin K antagonists were the only oral option available; however, they have a number of well-known limitations. Introduction of the direct oral anticoagulants (DOACs) has long been considered a major therapeutic advance, largely because they lack the need for therapeutic monitoring. Despite this, DOACs, like vitamin K antagonists, can still cause major and clinically relevant nonmajor bleeding, even when used appropriately. Drug-drug interactions (DDIs) involving the DOACs represent an important contributor to increased bleeding risk. Awareness of these DDIs and how best to address them is of critical importance in optimizing management while mitigating bleeding risk. This review provides an overview of DOAC metabolism, the most common drugs likely to contribute to DOAC DDIs, their underlying mechanisms, and how best to address them.